Press "Enter" to skip to content

BioInvent has enrolled first patient in a Phase I/IIa trial of the first-in-class anti-TNFR2 antibody BI-1808 for the treatment of patients with solid tumors and CTCL – BioSpace

admin 0

BioInvent has enrolled first patient in a Phase I/IIa trial of the first-in-class anti-TNFR2 antibody BI-1808 for the treatment of patients with solid tumors and CTCL  BioSpace
“lymphoma cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *